Display Settings:

Format

Send to:

Choose Destination
    Anticancer Res. 2008 Jan-Feb;28(1B):535-8.

    Clinicopathological features of lipomas with gene fusions involving HMGA2.

    Source

    Department of Orthopaedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan. hatanoh@niigata-cc.jp

    Abstract

    BACKGROUND:

    Despite accumulating knowledge of chimeric genes derived from fusion of the HMGA2 gene with multiple partners in lipomas, the different clinicopathological features of lipomas depending on different gene aberrations have not been well documented. The purpose of this study was to examine the clinical significance of the expression of fusion genes in lipomas.

    PATIENTS AND METHODS:

    The expressions of three previously reported gene fusion transcripts, including HMGA2/LPP, HMGA2/RDC1 and HMGA2/NFIB, were analyzed in 102 tumors from patients with lipomas.

    RESULTS:

    There were 23 cases (22.5%) expressing HMGA2/LPP, 2 cases (1.9%) expressing HMGA2/RDC1 and no cases of HMGA2/NFIB expression (0%). There were no significant intergroup differences in age, gender, body mass index, tumor size or location. The magnetic resonance images and pathological features were also not different in regard to the status of fusion gene expression.

    CONCLUSION:

    There were no significant differences of clinicopathological features in patients with lipoma with or without these fusion gene transcripts.

    PMID:
    18383898
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk